Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report

被引：9

作者：

Toriu, Naoya ^{[1
,2
]}

Sekine, Akinari ^{[1
,2
]}

Mizuno, Hiroki ^{[1
,2
]}

Hasegawa, Eiko ^{[1
,2
]}

Yamanouchi, Masayuki ^{[1
,2
]}

Hiramatsu, Rikako ^{[1
,2
]}

Hayami, Noriko ^{[1
,2
]}

Hoshino, Junichi ^{[1
,2
]}

Kawada, Masahiro ^{[1
,2
]}

Suwabe, Tatsuya ^{[1
,2
]}

Sumida, Keiichi ^{[1
,2
]}

Sawa, Naoki ^{[1
,2
]}

Takaichi, Kenmei ^{[1
,2
,4
]}

Ohashi, Kenichi ^{[3
,6
]}

Fujii, Takeshi ^{[3
]}

Matoba, Shuichiro ^{[5
]}

Ubara, Yoshifumi ^{[1
,2
,4
]}

机构：

[1] Toranomon Gen Hosp, Nephrol Ctr, Tokyo, Japan

[2] Toranomon Gen Hosp, Dept Rheumatol, Tokyo, Japan

[3] Toranomon Gen Hosp, Dept Pathol, Tokyo, Japan

[4] Okinaka Mem Inst Med Res, Tokyo, Japan

[5] Toranomon Gen Hosp, Colorectal Surg Unit, Dept Digest Surg, Tokyo, Japan

[6] Yokohama City Univ, Grad Sch Med, Dept Pathol, Yokohama, Kanagawa, Japan

来源：

CASE REPORTS IN ONCOLOGY | 2019年 / 12卷 / 02期

关键词：

Thrombotic microangiopathy; Bevacizumab; Nephrotic syndrome; Colorectal cancer; KIDNEY-DISEASES; VEGF;

D O I：

10.1159/000500716

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

An 88-year-old Japanese man received bevacizumab for colorectal cancer with liver and peritoneal metastasis, during which nephrotic range proteinuria occurred (7.66 g/day). Renal biopsy showed endothelial damage with subendothelial swelling and a double contour of the glomerular basement membrane, which indicated a diagnosis of thrombotic microangiopathy (TMA). After bevacizumab was stopped, proteinuria decreased to 1 g/day. During the clinical course, this patient had no extrarenal manifestations. This case suggests that renal injury induced by bevacizumab is characterized by nephrotic range proteinuria and histological TMA, and is a renal-limited condition that differs from systemic TMA related to thrombotic thrombocytopenic purpura.

引用

页码：391 / 400

页数：10

共 50 条

[1] BevacizumabProteinuria and renal-limited thrombotic microangiopathy: case report
Reactions Weekly, 2019, 1775 (1) : 101 - 101
[2] Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report
Yamada, Ryo
Okawa, Takao
Matsuo, Ken
Suzuki, Makoto
Mori, Noriko
Mori, Kiyoshi
BMC NEPHROLOGY, 2019, 20 (1)
[3] Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report
Ryo Yamada
Takao Okawa
Ken Matsuo
Makoto Suzuki
Noriko Mori
Kiyoshi Mori
BMC Nephrology, 20
[4] Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report
Masashi Nishikubo
Yoshimitsu Shimomura
Nobuhiro Hiramoto
Naohiko Sawamura
Takako Yamaguchi
Shigeo Hara
Takayuki Ishikawa
BMC Nephrology, 22
[5] Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report
Nishikubo, Masashi
Shimomura, Yoshimitsu
Hiramoto, Nobuhiro
Sawamura, Naohiko
Yamaguchi, Takako
Hara, Shigeo
Ishikawa, Takayuki
BMC NEPHROLOGY, 2021, 22 (01)
[6] Fruquintinib-induced renal-limited thrombotic microangiopathy: a case report
Zhao, Ruiping
Fan, Ruichen
Pan, Yan
Han, Yuze
Wang, Ying
Chen, Weidong
BMC NEPHROLOGY, 2024, 25 (01)
[7] Dasatinib/imatinibAcquired drug resistance and renal-limited thrombotic microangiopathy: case report
Reactions Weekly, 2025, 2057 (1) : 129 - 129
[8] A Case of Eltrombopag-Associated Renal-Limited Thrombotic Microangiopathy
Katz, Nurit S.
Gutierrez, Catherine
Yang, Yihe
Shah, Sujal I.
McMahon, Gearoid M.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 612 - 612
[9] Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literatures
Qinghua Yin
Na Guo
Xueli Zhou
Huan Xu
Song Lei
Ping Fu
Hui Zhong
BMC Nephrology, 23
[10] Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literatures
Yin, Qinghua
Guo, Na
Zhou, Xueli
Xu, Huan
Lei, Song
Fu, Ping
Zhong, Hui
BMC NEPHROLOGY, 2022, 23 (01)

← 1 2 3 4 5 →